FilingsTodayPharmsville
At a glance
Pharmsville filed 16 disclosures in the last 12 months, including 1 insider. The most recent key filing was on Jan 30.
Revenue for 2025 was ₩12.7B, down 23.9% on 2024. It made an operating loss of ₩673.1M. Debt was 3% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩4.9B and operating loss of ₩217.3M.
The 2025 annual report lists 23 employees with an average tenure of 1.9 years and average pay of ₩48.5M. Its 5 directors and auditors were paid ₩90.6M each on average. It paid ₩200 per common share in cash dividends, against ₩100 a year earlier (+100%). 이병욱 and related parties held 65.33% at year end.
From the 2025 annual report
Staff: 23 (14 men, 9 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩1.3B. Directors and auditors: 5, paid ₩453M in total.
Dividends (common shares)
| Fiscal year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash dividend per share | ₩200 | ₩100 | ₩100 |
| Payout ratio | 53.5% | 48.8% | 23.2% |
| Yield (as filed) | 5.82% | 2.63% | 1.16% |
| Total cash dividends | ₩1.5B | ₩772M | ₩774M |
Largest shareholder
이병욱 holds 50.50%; with 6 related parties the group holds 65.33% of common shares at year end (from 65.07% at the start of the year).
Auditor: 대주회계법인 · opinion: Unqualified.
Rankings: Dividend yield #86 of 1,084 · Dividend growth #93 of 917
Source: 2025 annual business report (DART). How figures are combined
Financial summary
Key filings
Other filings
Links open the original filing on DART, in Korean.